Literature DB >> 1534880

Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium.

K Bremme1, E Ostlund, I Almqvist, K Heinonen, M Blombäck.   

Abstract

Blood coagulation and fibrinolytic inhibitors and the balance between and within the two systems were investigated in 26 normal pregnant women during pregnancy and the puerperium. The concentration of the coagulation inhibitors antithrombin and protein C remained within normal levels, whereas the mean level of free protein S showed a significant decrease from 0.26 U/mL in early pregnancy to 0.14 U/mL in week 35. At the same time, soluble fibrin levels increased from 9.2 to 13.4 nmol/L and thrombin-antithrombin complexes increased from 3.1 to 7.1 micrograms/L; both are indicators of thrombin activity. A concurrent increase in the levels of the fibrinolytic inhibitors plasminogen activator inhibitor-1 and -2 from 7.4 to 37.8 AU/mL and 31 to 160 micrograms/L, respectively, suggests a decrease in fibrinolytic activity. However, the levels of fibrin D-dimer, ie, fibrin split products, also increased in parallel from 91 to 198 micrograms/L, suggesting that fibrinolysis is present. Thus, a balance normally exists, which is probably why thrombotic events are rare during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534880

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

1.  Decrease in protein C inhibitor activity and acquired APC resistance during normal pregnancy.

Authors:  H Shu; M Wramsby; M Bokarewa; M Blombäck; K Bremme
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

2.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

Review 3.  Emerging concepts in the diagnosis and management of venous thromboembolism during pregnancy.

Authors:  M M Burns
Journal:  J Thromb Thrombolysis       Date:  2000-08       Impact factor: 2.300

4.  Natural coagulation inhibitors and active protein c resistance in preeclampsia.

Authors:  Cengiz Demir; Imdat Dilek
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

5.  Elevated first trimester soluble fibrin polymer is associated with adverse pregnancy outcome in thrombophilic patients.

Authors:  Michael J Paidas; De-Hui W Ku; Gabriele Urban; Nazli Hossain; Andrei Rebarber; Charles J Lockwood; Yale S Arkel
Journal:  Blood Coagul Fibrinolysis       Date:  2008-12       Impact factor: 1.276

6.  Preanalytical conditions that affect coagulation testing, including hormonal status and therapy.

Authors:  M Blombäck; B A Konkle; M J Manco-Johnson; K Bremme; M Hellgren; R Kaaja
Journal:  J Thromb Haemost       Date:  2007-01-12       Impact factor: 5.824

7.  The clinical significance of D-dimer concentrations in patients with gestational hypertensive disorders according to the severity.

Authors:  Se Jeong Kim; Hyo Jeong Ahn; Jung Yeon Park; Byoung Jae Kim; Kyu Ri Hwang; Taek Sang Lee; Hye Won Jeon; Sun Min Kim
Journal:  Obstet Gynecol Sci       Date:  2017-10-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.